Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cue Biopharma (CUE) Interest & Investment Income (2018 - 2025)

Historic Interest & Investment Income for Cue Biopharma (CUE) over the last 8 years, with Q3 2025 value amounting to $222000.0.

  • Cue Biopharma's Interest & Investment Income fell 3527.7% to $222000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $880000.0, marking a year-over-year decrease of 6066.16%. This contributed to the annual value of $1.6 million for FY2024, which is 3904.55% down from last year.
  • Per Cue Biopharma's latest filing, its Interest & Investment Income stood at $222000.0 for Q3 2025, which was down 3527.7% from $198000.0 recorded in Q2 2025.
  • In the past 5 years, Cue Biopharma's Interest & Investment Income registered a high of $905000.0 during Q4 2023, and its lowest value of $3898.0 during Q4 2021.
  • Moreover, its 5-year median value for Interest & Investment Income was $222000.0 (2025), whereas its average is $316626.2.
  • As far as peak fluctuations go, Cue Biopharma's Interest & Investment Income plummeted by 9499.7% in 2021, and later soared by 1611344.28% in 2022.
  • Cue Biopharma's Interest & Investment Income (Quarter) stood at $3898.0 in 2021, then surged by 16113.44% to $632000.0 in 2022, then soared by 43.2% to $905000.0 in 2023, then crashed by 67.96% to $290000.0 in 2024, then dropped by 23.45% to $222000.0 in 2025.
  • Its Interest & Investment Income stands at $222000.0 for Q3 2025, versus $198000.0 for Q2 2025 and $170000.0 for Q1 2025.